2025. EFFICACY AND RISKS PROFILES OF “GLP-1 RECEPTOR AGONISTS” IN TYPE 2 DIABETES AND OBESITY: A SYSTEMATIC REVIEW OF BENEFITS AND RISKS. Review Journal of Neurological & Medical Sciences Review. 3, 5 (Sep. 2025), 300–324. DOI:https://doi.org/10.63075/fmkjkn28.